First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100

NCT01028521 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: CM3.1-AC100
DRUG: Placebo

Sponsor

CellMed AG, a subsidiary of BTG plc.